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Objectives. To determine if a widely available weight-management program (Weight
Watchers) could achieve sufﬁcient weight loss in persons with prediabetes compared
with a Diabetes Prevention Program–based individual counseling program supported by
National Diabetes Education Program materials.
Methods. We conducted an individual, randomized intervention trial in Indianapolis,
Indiana, in 2013 to 2014, in 225 persons with prediabetes. We compared the Weight
Watchersweight-managementprogram (n =112)with YourGamePlan toPrevent Type2
Diabetes, a program developed by the National Diabetes Education Program.Outcomes
were weight and metabolic markers measured at baseline, 6 months, and 12 months.
Results. Intervention participants lost signiﬁcantly more weight than controls at
6 months (5.5% vs 0.8%) and 12 months (5.5% vs 0.2%; both P< .001). The intervention
group also had signiﬁcantly greater improvements in hemoglobin A1c and high-density
lipoprotein cholesterol level than did controls.
Conclusions. A large weight-management program is effective for achieving lifestyle
changes associatedwith diabetes prevention. Such programs could signiﬁcantly increase
the availability of diabetes prevention programs worldwide making an immediate and
signiﬁcant public health impact. (Am J Public Health. 2016;106:949–956. doi:10.2105/
AJPH.2015.303035)
Type 2 diabetes is one of the most sig-niﬁcant public health crises of our time.
Both incidence and prevalence have
reached epidemic proportions, affecting
more than 29 million Americans1 with costs
exceeding $245 billion annually.2 Of par-
ticular concern is the estimated 86 million
persons with prediabetes in the United
States, a metabolic condition that signiﬁ-
cantly increases the risk for developing type
2 diabetes.2,3 If left unchallenged, there will
be a signiﬁcant increase in the number of
persons burdened by type 2 diabetes with
concomitant social and ﬁscal costs associated
with the disease.
Fortunately, the Diabetes Prevention
Program (DPP) demonstrated that type 2
diabetes risk can be reduced through modest
weight loss and increased physical activity
achieved through lifestyle change programs.4
Unfortunately, the DPP addressed efﬁcacy,
with little regard to the feasibility or costs
required to implement prevention programs
into the broader public health. There are
programs targeting the translation of the DPP
to the broader public health.5–9 These pro-
grams have been shown to be effective in
addressing the primary risk factor for de-
veloping type 2 diabetes—weight reduction
in persons with prediabetes.5–14 In spite of
more than a decade of evidence that diabetes
prevention is feasible, the speed at which
programs have become available is still rela-
tively slow.
There are limits to the scalability of pro-
grams that use the DPP curriculum format.
They are “disease speciﬁc” (i.e., they target
only persons with prediabetes). Although this
is consistent with the evidence base that
demonstrates the effectiveness of the DPP
format curriculum only for those with pre-
diabetes, given that excessive weight is the
prime risk factor, this may limit interest and
availability for persons who do not know they
have prediabetes—a condition that is still not
routinely assessed in primary care.15 Thus,
disease-speciﬁc programs may fail to reach
the critical mass required to start and scale
a cohort-based program (i.e., all participants
have to start at same time).
In addition, theDPP-based curriculum has
some inherent limitations that potentially
have an impact on the development of the
program on a broad public health scale. The
DPP uses a 16 weekly session sequential
curriculum in which each session is only
offered once. If a session ismissed, it is difﬁcult
to make it up. Increasing evidence illustrates
that it is difﬁcult for many persons to commit
to a 4-month weekly program.5–9 By con-
trast, many weight-loss programs use “loop”
models in which sessions are repeated fre-
quently and at a wide range of times and
locations, often within the same week. Such
programs are easy to restart when needed if
life events or scheduling conﬂicts interrupt
program attendance. This feature may offer
important alternatives to consumers in terms
of “user friendliness.”
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There is clearly a need to identify mech-
anisms that canmore quickly implement cost-
effective, evidence-based intervention programs.
In this context, the role that widely
available commercial weight-loss programs
might play has not been fully explored. There
are many scalable weight-management pro-
grams available in the commercial space.Most
incorporate the central components used in
the DPP—monitoring of food intake,
modiﬁcation in food selection to reduce
calories, focus on social and psychological
factors that inﬂuence eating behavior, and
the use of regular physical activity to help
with weight loss and maintenance. None of
these programs, however, has been tested
among those with prediabetes to determine
if they can achieve weight loss consistent
with risk reduction. If such programs can
produce weight loss among persons with
prediabetes comparable to that seen in the
DPP and derivative programs, and do so
at a reasonable cost, they could provide
a valuable approach to diabetes prevention
without the need for creating additional
infrastructure, disseminating complex
treatment programs, and training new
treatment providers.
To explore the potential of a widely
available weight-loss program to contribute
to the primary prevention of type 2 diabetes,
we investigated if the Weight Watchers
program, when combined with a single ses-
sion to address prediabetes, could effectively
reduce weight at levels similar to the DPP-
based community programs.
METHODS
This was an individual, randomized in-
tervention trial to evaluate the effects of
a modiﬁed version of the Weight Watchers
program compared with a self-initiated pro-
gram developed by the National Diabetes
Education Program on weight and glucose
control as measured by hemoglobin A1c
(Figure 1).
Participants
We screened potential participants for
eligibility in community settings. To be eli-
gible, a person had to be aged 18 years or
older, have a body mass index (BMI; deﬁned
as weight in kilograms divided by the square
of height inmeters) of 24 or higher (persons of
Asian descent BMI ‡ 23), and to complete
the 7-item American Diabetes Association
(ADA) Diabetes Risk Assessment with a score
of 5 or greater. In addition, they had to have
prediabetes, which was determined by a he-
moglobin A1c value between 5.7% and 6.5%.
Women with a self-reported history of ges-
tational diabetes with a hemoglobin A1c
value less than 6.5% or causal capillary blood
glucose (CCBG) less than 199 milligrams per
deciliter were also included. Persons were
noneligible if they had no evidence of pre-
diabetes; were currently pregnant or planning
to become pregnant during the study; had any
condition or used any medication that could
alter glucose metabolism; suffered heart at-
tack, stroke, or transient ischemic attack in the
past 6months; had uncontrolled hypertension
(systolic blood pressure > 180 mm Hg or
diastolic blood pressure > 105 mm Hg); re-
ceived treatment of cancer (excluding surgery
alone) within the past 2 years (excluding skin
cancer); reported chest pain, shortness of
breath with minimal activity or at rest, or
unexplained dizziness or fainting with phys-
ical activity; had chronic lung disease (chronic
obstructive pulmonary disease or asthma re-
quiring home oxygen therapy); current use of
antidiabetes medications for the treatment of
diagnosed diabetes; were unable to com-
municate with research staff; were unable to
read written English; and were unable or
unwilling to provide consent.
Multiple screening sessions were held at 8
community sites, including recreation cen-
ters, churches, and community clubhouses.
Hemoglobin A1c was determined by using
a DCA Vantage analyzer (Siemens, Malvern,
PA).16 The CCBG level was determined by
using a One-Touch Ultra handheld glucose
meter (Roche Diagnostics, Indianapolis,
IN).17 The ADA risk screener was used.18
People with an ADA risk score of 5 or greater,
a hemoglobin A1c from 5.7% to 6.4%, and
CCBG of 110 to 199 milligrams per deciliter
(100–109 mg/dL if fasting 8 or more hours)
were informed that theywere at increased risk
for developing diabetes and were potentially
eligible for the study. People with a hemo-
globin A1c of 6.5% or greater and a CCBG of
200 milligrams per deciliter or greater were
informed that they were at high risk for di-
abetes and should see a health care provider
immediately to undergo formal conﬁrmatory
testing and follow-up.
Measures
Measures were collected by an Indiana
University School of Medicine research team
from April 2013 to April 2014 at community
sites at baseline, 6 months, and 12 months of
study enrollment. The primary outcome was
percent change in body weight after 6 and
12 months. Body weight (and height) was
measured with a calibrated Detecto ProDoc
Series PD300MHR Digital Physician scale
(Cardinal, Webb City, MO) with mechanical
height rod and a Detecto 758C Weight In-
dicator with a Seca 213 Portable Stadiometer
(Cardinal, Webb City, MO).
Secondary outcomes included changes in
blood pressure, hemoglobin A1c, total cho-
lesterol, and HDL-cholesterol (HDL-c). Total
cholesterol and HDL-c were measured with
a Cholestech LDX lipid analyzer (Alere,
Providence, RI).19 Blood pressure was assessed
with an aneroid sphygmomanometer (Welch
Allyn, Skaneateles Falls, NY) and with an
Accutorr V vital signs monitor (Mindray,
Mahwah, NJ) with appropriate-sized cuff after
participants were seated and relaxed for at least
5 minutes. All research staff were trained in use
of this technology.This includedproper sample
collection, calibration of the equipment, and
data transfer to study forms.
Eligible and consented participants were
randomly assigned either to the intervention
or the control group in a 1-to-1 ratio with
a computer-generated randomization list
with a block size of 4. Assignment was done
by use ofREDCap version 6.5.20 (Vanderbilt
University, Nashville, TN), a secure Web-
based application that automated the
computer-based randomization list generated
by the biostatistician. Participants were in-
formed of treatment assignment at the con-
clusion of the baseline assessment.
Intervention and Controls
All screening participants received per-
sonalized advice about their risk for de-
veloping diabetes, and those without
contraindications were advised that modest
weight loss (5%–10%) via caloric restriction
and the adoption ofmoderate physical activity
were generally safe and effective in preventing
or delaying the onset of diabetes. This advice
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typically took 5 minutes via an individual
session with a trained research assistant and
was supplemented by use of Small Steps,
Big Rewards educational materials available
from the National Diabetes Education
Program.20,21
The intervention was the lifestyle modi-
ﬁcation program offered byWeightWatchers
International. The Weight Watchers core
curriculum is evidence-based15,22–24 and
covers the same behavioral topics used in the
DPP:
1. self-monitoring of weight, intake, and
activity;
2. dietary modiﬁcation;
3. physical activity;
4. stimulus control; and
5. relapse prevention.
1
Analysed for intent-to-treat analysis (n = 103 at 
6 mo; n = 94 at 12 mo) 
Excluded from analysis (give reasons) (n = 9 
at 6 mo; n = 18 at 12 mo); no data available 
Analysed for sensitivity analysis (n = 112)
Lost to follow-up (give reasons; n = 18) 
 Relocation (n = 0 ) 
 Health status (n = 0) 
 Refused follow-up data collection/no 
longer interested in study (n = 1) 
 Unable to contact/no reason given 
(n = 17) 
 Unable to attend follow-up data 
collection (lack of transportation, 
schedule conflicts, etc.; n = 0) 
Allocated to intervention (n = 112) 
Lost to follow-up (give reasons; n = 32) 
 Relocation (n = 1) 
 Health status (n = 2) 
 Refused follow-up data collection/no 
longer interested in study (n = 2) 
 Unable to contact/no reason given 
(n = 26) 
 Unable to attend follow-up data 
collection (lack of transportation, 
schedule conflicts, etc.; n = 1) 
Allocated to control (n = 113) 
Analysed for intent-to-treat analysis (n = 82 at 6 
mo; n = 81 at 12 mo) 
Excluded from analysis (give reasons) (n = 31 
at 6 mo; n = 32 at 12 mo); no data available 
Analysed for sensitivity analysis (n = 113)
Allocation
Analysis
Follow-Up
Enrollment
Assessed for eligibility (n = 475) 
Excluded (n = 250) 
Not meeting inclusion criteria (n = 244) 
Declined to participate (n = 6) 
Other reasons (n = 0) 
Randomized (n = 225) 
FIGURE 1—Consort Flow Diagram for Randomized Controlled Trial of Weight Watchers Versus CounselingWith National Diabetes Education
Program Materials: Indianapolis, IN, 2013–2014
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The curriculum is delivered in a support-
ive, weekly group environment by appro-
priately trained group leaders.
Before beginning the lifestyle intervention
program, participants attended a 45-minute
“activation” session at 1 of 5 WW facilities in
the Indianapolis area. This was done within
1week of the baseline assessment. This session
was conducted by existingWW coaches who
were trained for this study-speciﬁc session. It
focused on educating participants about the
meaning of prediabetes, how the condition
increases risk for developing type 2 diabetes,
and the role of lifestylemodiﬁcation to reduce
their risk. A weight loss goal of 7% was also
assigned. Following this activation session,
participants were enrolled into the already
existing Weight Watchers program in the
community. Participants were free to choose
a Weight Watchers group session time and
location that was convenient for them. Par-
ticipants attended already existing meetings
that were not study-speciﬁc and included
those without prediabetes. They were en-
couraged to attend the weekly meetings and
told they were free to switch both time and
location as best ﬁt their schedules. They were
also given access to the Weight Watchers
e-tools, which includes digital tools to track
weight, intake, and activity as well as tips to
facilitate adherence. All Weight Watchers
services and sessions were provided free of
charge for the duration of the study.
Participants assigned to the control con-
dition were provided a review of how they
could initiate a weight loss and activity
program with Your Game Plan to Prevent
Type 2 Diabetes educational materials de-
veloped by theNational Diabetes Education
Program.20,21 These materials review the
meaning and implications of prediabetes,
the results of the DPP study, an overview of
how to initiate a risk-reducing lifestyle
program, a reproducible tracker to help
monitor their food intake, and a booklet
with fat gram and calorie content for
common foods. Emphasis was placed on
strategies for tracking food intake and cal-
culating fat grams by using the food tracker
and calorie fat gram guide provided in the
materials. This individual counseling, which
took approximately 15 minutes, was pro-
vided by trained research staff and con-
ducted during the screening event after
randomization.
The primary efﬁcacy outcome was the
percent weight change from baseline to
6 months and 12 months. In our Diabetes
Education and Prevention with a Lifestyle
Intervention Offered at the YMCA
(DEPLOY) study,9 the interventiongrouphad
a 6.0% loss of weight (95% conﬁdence interval
[CI]= 3.8%, 8.3%) with a variability of 4.3%,
and the control group experienced a mean
weight reduction of 1.8% (95% CI= –0.3%,
3.9%) with a variability of 4.1% at 12 months.
There was a 15% dropout rate at 6 months and
18% at 12 months. Assuming a common
variability of 4.3%, therewas a 90% probability
that the halfwidth of the 95%CI for estimating
the mean percent weight change would be no
more than 1.1% for a sample size of 85 per
group.Also,with a conservative estimate of 3%
weight reduction for the intervention group
and 1% weight reduction for the control
group, a sample size of 85 per group had 85%
power at 5% type I error rate. To account for
a 15% dropout rate, we planned to recruit 100
participants per group.
Statistical Analyses
We summarized all baseline continuous
variables by using descriptive statistics and
presented them by treatment group. We
summarized categorical variables with fre-
quency counts and percentages. We com-
pared baseline clinical and demographic data
among the 2 groups. We examined di-
chotomous and ordinal variables by using
either c2 test or Fisher exact test and con-
tinuous measures with 2-sample t test or 2
sample nonparametric Wilcoxon Rank Sum
Test (if normality assumptions are not met).
The primary outcomes were the percent
weight change at 6 and 12 months from
baseline. We modeled the longitudinal data
on percent weight change at 6 and 12months
by using repeated-measures analysis of co-
variance. Secondary outcomes included
changes in hemoglobin A1c, blood pressure,
glucose level, total cholesterol, and HDL-c.
Again, we used repeated-measures analysis of
covariance to analyze all the secondary out-
comes. We also analyzed the proportion of
participants with at least 5%weight loss as well
as the proportion of participants with at least
7% weight loss at 6 and 12 months. We used
logistic regression models with generalized
estimating equations. All models included
baseline value of the outcome variable, total
cholesterol, and diastolic blood pressure. We
used an unstructured covariance matrix in all
models. To account for missing weight data
(27% at 6 months and 28% at 12 months in
control group; 8% at 6 months and 16% at
12 months in the intervention group), we
performed sensitivity analysis with multiple
imputation method with the assumption that
missing data at follow-up was a function of
treatment group and baseline weight.
RESULTS
The study sample was primarily female
(85%), non-Hispanic (94%), andWhite (64%)
with 88% having at least 1 year of college and
70%having an annual household income of at
least $35 000. Participants were aged on av-
erage 52 (SD=11) years with a BMI of 36.8
(SD= 7.1) and baseline weight 100.63
(SD= 20.8) kilograms. Table 1 shows base-
line characteristics by treatment group. There
were no differences between groups on
baseline characteristics, except that control
participants had slightly higher total choles-
terol and lower diastolic blood pressure than
the intervention group.
Changes in body weight and clinical
outcomes are shown in Table 2. The in-
tervention group lost signiﬁcantly more
weight than controls at both 6 and 12 months
(P values < .001). On average, controls lost
0.8% (SE= 0.5%) at 6 months and 0.2%
(SE= 0.7%) at 12 months and intervention
participants lost 5.5% (SE= 0.5%–0.6%) both
at 6 and 12months (Figure 2). This translated,
on average, to 4.6 (SE= 0.70) kilogramsmore
weight loss at 6 months and 5.3 (SE= 0.94)
kilograms more weight loss at 12 months for
intervention participants than controls. The
sensitivity analyses for treatment difference
showed either identical or almost the same
results at 6 months and 12 months; that
is, mean treatment differences were 4.7%
(SE = 0.68%) at 6 months and 5.3%
(SE= 0.93%) at 12months whenwe analyzed
data without any imputation for missing
values versus 4.7% (SE= 0.68%) at 6 months
and 5.5% (SE= 1.00%) at 12 months when
were analyzed data withmultiple imputations
for missing values.
There was a greater proportion in the
intervention group who had 5% or greater
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weight loss, as well as 7% or greater weight
loss, which deﬁnes the range in which risk
reduction is felt to occur.4 The odds of
achieving 5% or greater weight loss for the
intervention group was 6.9 times greater
(P<.001) than the control group at 6 months
and 4.7 times greater (P< .001) at 12 months.
In a similar way, the odds of achieving 7% or
greater weight loss for the intervention group
were 6.2 times greater (P < .001) than controls
at 6 months and 5.0 times greater (P < .001) at
12 months.
Among secondary outcomes, the in-
tervention group showed signiﬁcantly greater
improvements than controls at 6 and 12
months, in hemoglobin A1c (-0.22 vs –0.14;
P= .032) and 3.3 milligrams per deciliter
greater increases in HDL-c (P= .036). There
were no signiﬁcant differences between
groups on any of the other secondary out-
comes. We also calculated the average
number of group sessions that participants in
the Weight Watchers condition attended
to determine what the “dose” of the in-
terventionwas. The average number of group
sessions attended during the study over
a 1-year periodwas 21.6 (range = 1–55). Also,
63% reported using the online app; however,
we did not assess howmany used both live and
app opportunities. Anecdotal evidence sug-
gests that many users attended groups and
used the app to record dietary intake and
calculate points.
DISCUSSION
The incidence of diabetes has reached
epidemic proportions and illuminates the
need to rapidly expand community access
to evidence-based prevention programs.
Although such programs continue to increase,
there are still far too few to meet the
current and expanding public health need.
The data from this study show that a widely
available weightmanagement program results
in changes in body weight after 6 and
12 months that are comparable to those
observed in the DPP study and community
adaptations.6–14,25–28
The program studied here, Weight
Watchers, is a widely available, evidence-
based lifestyle intervention that combines
face-to-face and digital offerings. There are
more than 25 000WeightWatchers meetings
TABLE 1—Baseline Characteristics of Study Participants in Randomized Controlled Trial of
Weight Watchers Versus Counseling With National Diabetes Education Program Materials:
Indianapolis, IN, 2013–2014
Characteristics
WW Intervention
(n = 112), Mean (SD) or %
Control (n = 113),
Mean (SD) or % P
Demographics
Age, y 51.5 (11.5) 51.7 (11.0) .89
Gender, female 83.0 86.7 .44
Ethnicity, non-Hispanic 93.7 93.7 .45
Race .64
White 63.4 65.5
African American 28.6 22.1
Asian/Paciﬁc Islander 5.4 8.0
Multiracial 1.8 1.8
Other 0.9 2.6
Education .98
Some high school 1.8 2.8
High-school graduate or GED 9.8 10.1
Some college or 2-y college degree 34.8 33.0
4-y college graduate 17.9 20.2
> 4-y college degree 35.7 33.9
Marital status .54
Married 59.8 53.6
Divorced 19.6 26.4
Never married 14.3 11.8
Widowed 4.5 2.7
Separated 0.9 2.7
Living with partner 0.9 2.7
Income, $ .58
< 10 000 1.8 0.9
10 000–15 000 2.7 4.5
> 15 000–25 000 7.1 1.8
> 25 000–35 000 10.7 14.5
> 35 000–50 000 17.0 16.4
> 50 000–75 000 19.6 19.1
> 75 000 33.0 35.4
Didn’t know 4.5 1.8
Refused 3.6 5.4
Clinical variables
Baseline weight in kg 100.9 (21.7) 100.0 (19.9) .74
Body mass index, kg/m2 36.9 (7.3) 36.7 (7.0) .89
Hemoglobin A1c, % 5.9 (0.3) 5.8 (0.3) .11
Glucose, mg/dL 107.6 (21.3) 110.0 (21.6) .41
Total cholesterol, mg/dL 186.2 (31.5) 195.6 (38.3) .047
HDL-c, mg/dL 47.8 (14.2) 47.6 (14.1) .91
Diastolic blood pressure, mm Hg 82.6 (8.3) 80.2 (8.7) .032
Systolic blood pressure, mm Hg 130.9 (12.7) 129.5 (15.1) .45
Note. GED=general equivalency diploma; HDL-c = high-density lipoprotein cholesterol; WW=Weight
Watchers.
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held each week in the United States, led by
trained facilitators in a variety of times and
locations, including more than 5000 in
workplace settings. Thus, Weight Watchers
has the potential for rapidly expanding access
to a lifestyle intervention for those with
prediabetes that signiﬁcantly exceeds the
reach of current efforts. The potential to
achieve weight-loss levels could translate into
considerable reductions in diabetes risk.
An important consideration when one is
assessing models for scaling up diabetes pre-
vention programs is cost. A recent meta-
analysis of 1-year randomized trials of various
commercial weight-loss approaches found
that Weight Watchers was the most cost-
effective.29 The cost of participating in
Weight Watchers is $515.40 per year for
unlimited access to group sessions anywhere
in the country and includes access to their
eTools and mobile app. The online program
alone is $227.40 per year. This compares
favorably with $429 charged by the national
YMCADiabetes Prevention Program, which
offers 24 rigidly scheduled sessions in a year.30
It is important to note, however, that the
YMCA offers income-based fee scaling. El-
igible individuals pay anywhere from $0 to
$429 out of pocket. When one is considering
costs, there is growing acceptance by the
insurance industry to pay the costs of par-
ticipating in evidence-based prevention
programs.31–33 If this expands to weight-
management programs that can demonstrate
effectiveness delivered with ﬁdelity, the ability
to expand access to a broad public health
scale quickly is a probable outcome with sig-
niﬁcant impacts on diabetes prevention.
The lack of differences between the 2
groups in lipids and blood pressure is sur-
prising in light of the well-documented ef-
fects of weight loss on cardiovascular disease
risk factors. Unlike the DPP-based in-
tervention, Weight Watchers does not spe-
ciﬁcally target fat gram control, which may
explain why there were no changes in lipids
observed. It is more likely, however, that the
baseline values within normal limits (Table 1)
provided a restricted range to see weight-loss
effects. There was, however, a signiﬁcantly
greater reduction in hemoglobin A1c among
intervention versus controls. This is consistent
with the effects of weight loss on hemoglobin
A1c among those with prediabetes. This was
also the case in the DEPLOY study of
adapting the DPP for delivery in the YMCA
where weight loss was observed but not
differences in lipids in the control group.10
One aspect of the intervention described
here is the use of an activation session.We did
not design this study to assess the importance
of this to the overall impact. We chose to use
the activation session as a means to better
acquaint participants with their risk status and
to assign a 7% weight-loss goal. We believe
that this session helped to motivate the par-
ticipants and should be considered as a feature
of a national Weight Watchers prevention
effort.
Limitations
There are limitations to this study thatmust
be considered. There was a loss of participants
to follow-up at 12 months. Thus, for the
primary weight-loss outcome, the effective-
ness of the intervention may have been
overestimated if weight loss was lower in
nonrespondents. There were, however,
fewer participants lost to follow up in the
intervention (16%) versus control (28%)
group. As loss to follow up was greater in the
control group, the group differences observed
might have been even greater if all participants
were represented. Sensitivity analyses showed
the same results—mean treatment differences
were 4.7% (SE= 0.68%) at 6 months and
5.5% (SE= 1.0%) at 12 months with statistical
adjustment for baseline differences in con-
founders, total cholesterol, and diastolic blood
pressure.However, itwas not possible to adjust
for all potential confounders in this study.
In addition, the majority of the sample
were women and the Weight Watchers
sample also had higher socioeconomic status
and education status.Recruitment targeted all
residents of the Indianapolis metropolitan
area. Thus, there was no attempt to exclude
men or any group on the basis of their
socioeconomic status. This may reﬂect
a tendency of women to gravitate toward
diet-modiﬁcation programs.34 It does caution
against generalizing the results of this study to
TABLE 2—Changes in BodyWeight and Clinical Outcomes in Randomized Controlled Trial of
Weight Watchers Versus Counseling With National Diabetes Education Program Materials:
Indianapolis, IN, 2013–2014
Outcomes WW Intervention, No. or Mean (SD) Control, No. or Mean (SD) P
At 6 mo from baseline 103 82
Baseline weight in kg 100.9 (10.58) 100.0 (10.63) .74
Percent weight change –5.53 (0.45) –0.82 (0.50) <.001
Weight in kg –5.49 (0.46) –0.91 (0.51) <.001
Body mass index, kg/m2 –2.03 (0.17) –0.30 (0.19) <.001
Hemoglobin A1c, % –0.22 (0.02) –0.14 (0.03) .032
Glucose, mg/dL –5.47 (1.78) –2.06 (1.99) .21
Total cholesterol, mg/dL –4.33 (2.52) –1.75 (2.80) .499
HDL-c, mg/dL 2.48 (0.96) –0.05 (1.07) .084
Systolic blood pressure, mm Hg –3.31 (1.11) –2.99 (1.24) .85
Diastolic blood pressure, mm Hg –4.39 (0.89) –4.80 (0.99) .76
At 12 mo from baseline 94 81
Baseline weight in kg 100.9 (10.58) 100.0 (10.63) .74
Percent weight change –5.55 (0.62) –0.21 (0.68) <.001
Weight in kg –5.51 (0.63) –0.22 (0.69) <.001
Body mass index, kg/m2 –2.06 (0.23) –0.07 (0.25) <.001
Hemoglobin A1c, % –0.25 (0.03) –0.18 (0.03) .068
Glucose, mg/dL –2.77 (2.10) –1.97 (2.27) .80
Total cholesterol, mg/dL 0.45 (2.46) –0.61 (2.66) .77
HDL-c, mg/dL 6.29 (1.05) 2.99 (1.14) .036
Systolic blood pressure, mm Hg –3.30 (1.18) –3.39 (1.27) .96
Diastolic blood pressure, mm Hg –5.39 (0.92) –5.77 (0.99) .78
Note. HDL-c = high-density lipoprotein cholesterol; WW=Weight Watchers.
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low-socioeconomic status populations and
men.
Conclusions
These data suggest that Weight Watchers,
a widely available, empirically validated
weight-management program, could offer
a potential tool to signiﬁcantly expand access
to diabetes prevention programs in com-
munity settings and produce weight-loss
levels that translate into considerable re-
ductions in diabetes risk. The role that
commercial programs can play in diabetes
prevention among those at high risk for
diabetes deserves future study.35,36
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